Search research articles
Contact Us
Filters
Showing results (101-110 of 120) with videos related to
Page
of 12
Sort By:
BMJ Open Gastroenterology
|
January 8, 2025
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis
Séverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 17, 2007
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
Tesfaye Biftu, Giovanna Scapin, Suresh Singh, et al.
JMIR Public Health and Surveillance
|
January 26, 2026
Establishing One Health Surveillance Platform for Electronic Integrated Disease Surveillance and Response in Malawi: Action Design Research Study
Tsung-Shu Joseph Wu, Matthew Vundu Mvula, Edward Kada Koma Chado, et al.
Rheumatology and Therapy
|
June 8, 2020
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Peter Nash, Laura C Coates, Alan J Kivitz, et al.
Annals of the Rheumatic Diseases
|
September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
Annals of the Rheumatic Diseases
|
January 31, 2023
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Maxime Dougados, Christina Charles-Schoeman, Zoltán Szekanecz, et al.
The Lancet. Rheumatology
|
January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Peter Nash, Philip J Mease, Dona Fleishaker, et al.
Plos One
|
May 4, 2023
Six months survival and risk factors for attrition for patients detected with cryptococcal antigenemia through screening in Malawi
Master R O Chisale, Alex Jordan, Pocha S Kamudumuli, et al.
Vaccine
|
February 7, 2024
Report from the World Health Organization's immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11-13 September 2023
Philipp Lambach, Walt Orenstein, Sheetal Silal, et al.
Journal of Medical Internet Research
|
October 20, 2021
Effectiveness of Smartphone-Based Community Case Management on the Urgent Referral, Reconsultation, and Hospitalization of Children Aged Under 5 Years in Malawi: Cluster-Randomized, Stepped-Wedge Trial
Griphin Baxter Chirambo, Matthew Thompson, Victoria Hardy, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 120) with videos related to
Sort By:
Page
of 12
BMJ Open Gastroenterology
|
January 8, 2025
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis
Séverine Vermeire, David T Rubin, Laurent Peyrin-Biroulet, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 17, 2007
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
Tesfaye Biftu, Giovanna Scapin, Suresh Singh, et al.
JMIR Public Health and Surveillance
|
January 26, 2026
Establishing One Health Surveillance Platform for Electronic Integrated Disease Surveillance and Response in Malawi: Action Design Research Study
Tsung-Shu Joseph Wu, Matthew Vundu Mvula, Edward Kada Koma Chado, et al.
Rheumatology and Therapy
|
June 8, 2020
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Peter Nash, Laura C Coates, Alan J Kivitz, et al.
Annals of the Rheumatic Diseases
|
September 22, 2022
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, et al.
Annals of the Rheumatic Diseases
|
January 31, 2023
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
Maxime Dougados, Christina Charles-Schoeman, Zoltán Szekanecz, et al.
The Lancet. Rheumatology
|
January 26, 2024
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Peter Nash, Philip J Mease, Dona Fleishaker, et al.
Plos One
|
May 4, 2023
Six months survival and risk factors for attrition for patients detected with cryptococcal antigenemia through screening in Malawi
Master R O Chisale, Alex Jordan, Pocha S Kamudumuli, et al.
Vaccine
|
February 7, 2024
Report from the World Health Organization's immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11-13 September 2023
Philipp Lambach, Walt Orenstein, Sheetal Silal, et al.
Journal of Medical Internet Research
|
October 20, 2021
Effectiveness of Smartphone-Based Community Case Management on the Urgent Referral, Reconsultation, and Hospitalization of Children Aged Under 5 Years in Malawi: Cluster-Randomized, Stepped-Wedge Trial
Griphin Baxter Chirambo, Matthew Thompson, Victoria Hardy, et al.
Page
of 12